NCT00099190View on ClinicalTrials.gov

ARQ 501 in Combination With Docetaxel in Patients With Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions
Carcinoma
Interventions
DRUG

ARQ 501

Trial Locations (1)

75246

Mary Crowley Medical Research Center, Dallas

All Listed Sponsors
lead

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

INDUSTRY

NCT00099190 - ARQ 501 in Combination With Docetaxel in Patients With Cancer | Biotech Hunter | Biotech Hunter